Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?Zacks Investment Research • 12/04/25
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should KnowZacks Investment Research • 11/18/25
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/25
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025GlobeNewsWire • 11/08/25
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025GlobeNewsWire • 10/17/25
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune DiseasesGlobeNewsWire • 10/07/25
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathyGlobeNewsWire • 09/02/25
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/25
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA NephropathyGlobeNewsWire • 06/09/25
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association CongressGlobeNewsWire • 06/02/25
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/25
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/13/25